Adaptimmune Quarterly report [Sections 13 or 15(d)]

Marketable securities - available-for-sale debt securities (Tables)

3 Months Ended

Mar. 31, 2025

As of March 31, 2025, the Company had the following investments in marketable securities (in thousands):


				Gross		Gross		Aggregate
	Remaining	Amortized		unrealized		unrealized		estimated
	contractual maturity	cost		gains		losses		fair value
Cash equivalents:
U.S. Treasury securities	Less than 3 months	$	6,988	$	—	$	—	$	6,988
Corporate debt securities	Less than 3 months		2,205		—		—		2,205
		$	9,193	$	—	$	—	$	9,193

Available-for-sale debt securities:
Corporate debt securities	Less than 3 months		6,582		—		(2)		6,580
U.S. Treasury securities	Less than 3 months		11,930		—		(1)		11,929
		$	18,512	$	—	$	(3)	$	18,509